Abstract
Obesity, a condition already at epidemic proportions in the developed world, is largely attributable to an indulgent lifestyle. Biologically we feel hunger more acutely than feeling ;full-up; (satiety). The discovery over a decade ago of leptin, an adiposity signal, revolutionised our understanding of hypothalamic mechanisms underpinning the central control of ingestive behaviour. The structure and function of many hypothalamic peptides (Neuropeptide Y (NPY), Melanocortins, Agouti related peptide (AGRP), Cocaine and amphetamine regulated transcript (CART), Melanin concentrating hormone (MCH), Orexins and endocannabinoids) have been characterised in rodent models. The pharmacological potential of several endogenous peripheral peptides released prior to, during and/or after feeding are being explored. Short-term signal hormones including Cholecystokinin (CCK), Ghrelin, Peptide YY (PYY3-36) and Glucagon-like peptide 1 (GLP-1) control meal size via pathways converging on the hypothalamus. Long-term regulation is provided by the main circulating hormones leptin and insulin. These systems among others, implicated in hypothalamic appetite regulation all provide potential “drugable” targets by which to treat obesity.
Keywords: food intake, obesity, energy homeostasis, hypothalamus
Current Drug Targets
Title: The Hypothalamus and Obesity
Volume: 6 Issue: 2
Author(s): Peter J. King
Affiliation:
Keywords: food intake, obesity, energy homeostasis, hypothalamus
Abstract: Obesity, a condition already at epidemic proportions in the developed world, is largely attributable to an indulgent lifestyle. Biologically we feel hunger more acutely than feeling ;full-up; (satiety). The discovery over a decade ago of leptin, an adiposity signal, revolutionised our understanding of hypothalamic mechanisms underpinning the central control of ingestive behaviour. The structure and function of many hypothalamic peptides (Neuropeptide Y (NPY), Melanocortins, Agouti related peptide (AGRP), Cocaine and amphetamine regulated transcript (CART), Melanin concentrating hormone (MCH), Orexins and endocannabinoids) have been characterised in rodent models. The pharmacological potential of several endogenous peripheral peptides released prior to, during and/or after feeding are being explored. Short-term signal hormones including Cholecystokinin (CCK), Ghrelin, Peptide YY (PYY3-36) and Glucagon-like peptide 1 (GLP-1) control meal size via pathways converging on the hypothalamus. Long-term regulation is provided by the main circulating hormones leptin and insulin. These systems among others, implicated in hypothalamic appetite regulation all provide potential “drugable” targets by which to treat obesity.
Export Options
About this article
Cite this article as:
King J. Peter, The Hypothalamus and Obesity, Current Drug Targets 2005; 6 (2) . https://dx.doi.org/10.2174/1389450053174587
DOI https://dx.doi.org/10.2174/1389450053174587 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Current Pharmaceutical Biotechnology Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier
Current Cancer Drug Targets Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Relevance of Dyslipidaemia and its Consequences in Periodontal Patients with Co-Existing Cardiovascular Disease and Diabetes Mellitus: Therapeutic Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands
Mini-Reviews in Medicinal Chemistry Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Probiotic Research in Australia, New Zealand and the Asia-Pacific Region
Current Pharmaceutical Design Flavaglines: Their Discovery from Plants Used in Traditional Chinese Medicine, Synthesis, and Drug Development Against Cancer and Immune Disorders
Current Chinese Chemistry Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119
Current Radiopharmaceuticals Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Histone Deacetylase Inhibitors In Inflammatory Disease
Current Topics in Medicinal Chemistry Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy